SCYNEXIS, Inc. (SCYX): Price and Financial Metrics
GET POWR RATINGS... FREE!
SCYX POWR Grades
- SCYX scores best on the Value dimension, with a Value rank ahead of 64.31% of US stocks.
- SCYX's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
- SCYX's current lowest rank is in the Stability metric (where it is better than 7.75% of US stocks).
SCYX Stock Summary
- SCYX has a market capitalization of $130,020,290 -- more than approximately merely 16.24% of US stocks.
- With a year-over-year growth in debt of 102.07%, Scynexis Inc's debt growth rate surpasses 91.75% of about US stocks.
- Scynexis Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -92.16%, greater than the shareholder yield of only 2.62% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Scynexis Inc are MOSY, HSTO, APVO, KLIC, and ICCC.
- Visit SCYX's SEC page to see the company's official filings. To visit the company's web site, go to www.scynexis.com.
SCYX Valuation Summary
- In comparison to the median Healthcare stock, SCYX's price/sales ratio is 11.01% higher, now standing at 12.6.
- SCYX's EV/EBIT ratio has moved up 1.3 over the prior 89 months.
- SCYX's EV/EBIT ratio has moved up 1.3 over the prior 89 months.
Below are key valuation metrics over time for SCYX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SCYX | 2021-08-31 | 12.6 | 4.7 | -3.4 | -1.8 |
| SCYX | 2021-08-30 | 12.2 | 4.6 | -3.3 | -1.7 |
| SCYX | 2021-08-27 | 12.3 | 4.6 | -3.3 | -1.7 |
| SCYX | 2021-08-26 | 11.9 | 4.4 | -3.2 | -1.6 |
| SCYX | 2021-08-25 | 12.1 | 4.5 | -3.2 | -1.6 |
| SCYX | 2021-08-24 | 12.3 | 4.6 | -3.3 | -1.7 |
SCYX Growth Metrics
- Its 5 year price growth rate is now at -86.84%.
- Its 5 year revenue growth rate is now at -99.35%.
- The 5 year net cashflow from operations growth rate now stands at -125.18%.
The table below shows SCYX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-06-30 | 12.05 | -38.895 | -44.82 |
| 2021-03-31 | 12.05 | -36.056 | -52.859 |
| 2020-12-31 | 0 | -49.354 | -55.185 |
| 2020-09-30 | 0 | -46.24 | -26.932 |
| 2020-06-30 | 0 | -46.773 | -35.782 |
| 2020-03-31 | 0.057 | -45.675 | -37.804 |
SCYX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SCYX has a Quality Grade of C, ranking ahead of 30.64% of graded US stocks.
- SCYX's asset turnover comes in at 0.134 -- ranking 233rd of 677 Pharmaceutical Products stocks.
- ACER, MNOV, and OVID are the stocks whose asset turnover ratios are most correlated with SCYX.
The table below shows SCYX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.134 | 1 | -3.908 |
| 2021-03-31 | 0.169 | 1 | -5.208 |
| 2020-12-31 | 0.000 | NA | -3.192 |
| 2020-09-30 | 0.000 | NA | -1.322 |
| 2020-06-30 | 0.000 | NA | -1.486 |
| 2020-03-31 | 0.001 | 1 | -1.353 |
SCYX Price Target
For more insight on analysts targets of SCYX, see our SCYX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $24.36 | Average Broker Recommendation | 1.36 (Strong Buy) |
SCYX Stock Price Chart Interactive Chart >
SCYX Price/Volume Stats
| Current price | $5.51 | 52-week high | $10.25 |
| Prev. close | $5.73 | 52-week low | $4.20 |
| Day low | $5.45 | Volume | 105,407 |
| Day high | $5.69 | Avg. volume | 511,582 |
| 50-day MA | $6.43 | Dividend yield | N/A |
| 200-day MA | $7.52 | Market Cap | 127.93M |
SCYNEXIS, Inc. (SCYX) Company Bio
SCYNEXIS, Inc., a pharmaceutical company, develops and commercializes novel anti-infectives to address unmet therapeutic needs. Its lead product candidate includes SCY-078, which is in Phase I clinical trials of the intravenous formulation; Phase II clinical trials for the treatment of invasive candida infections; and Phase II clinical trials for unmet medical needs, such as vulvovaginal candidiasis. The company was founded in 1999 and is based in Jersey City, New Jersey.
Latest SCYX News From Around the Web
Below are the latest news stories about Scynexis Inc that investors may wish to consider to help them evaluate SCYX as an investment opportunity.
SCYNEXIS to Present Data on Oral Ibrexafungerp at IDWeek 2021 from Interim Analyses of Phase 3 FURI Clinical Trial Showing Therapeutic Response Rates in Patients with Mucocutaneous and Invasive Fungal InfectionsAnalysis of subpopulations from a total of 74 patients evaluated to date from FURI includes outcomes by disease, bone and joint infections, and mouth and throat candidiasis Analysis of subpopulations from a total of 74 patients evaluated to date from FURI includes outcomes by disease, bone and joint infections, and mouth and throat candidiasis |
SCYNEXIS Announces U.S. Availability of BREXAFEMME® (ibrexafungerp tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 YearsJERSEY CITY, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced the U.S. availability of BREXAFEMME ® (ibrexafungerp tablets), the first and only oral non-azole prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat vulvovaginal candidiasis (VVC), commonly referred to as vaginal yeast infection. |
What Kind Of Shareholders Own SCYNEXIS, Inc. (NASDAQ:SCYX)?A look at the shareholders of SCYNEXIS, Inc. ( NASDAQ:SCYX ) can tell us which group is most powerful. Generally... |
SCYNEXIS Announces Hansoh Pharmas Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)Submission is part of the Hansoh Pharma licensing agreement and strategic partnership to research, develop and commercialize ibrexafungerp in the Greater China region Submission is part of the Hansoh Pharma licensing agreement and strategic partnership to research, develop and commercialize ibrexafungerp in the Greater China region |
SCYNEXIS Announces Hansoh Pharma’s Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)Submission is part of the Hansoh Pharma licensing agreement and strategic partnership to research, develop and commercialize ibrexafungerp in the Greater China regionJERSEY CITY, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) has filed an investigational new drug |
SCYX Price Returns
| 1-mo | -13.91% |
| 3-mo | -25.14% |
| 6-mo | -33.45% |
| 1-year | 22.72% |
| 3-year | -54.08% |
| 5-year | -85.50% |
| YTD | -27.97% |
| 2020 | -15.93% |
| 2019 | 89.58% |
| 2018 | -79.31% |
| 2017 | -27.27% |
| 2016 | -48.63% |
Continue Researching SCYX
Want to do more research on Scynexis Inc's stock and its price? Try the links below:Scynexis Inc (SCYX) Stock Price | Nasdaq
Scynexis Inc (SCYX) Stock Quote, History and News - Yahoo Finance
Scynexis Inc (SCYX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...